Alnylam facing patent dispute over Onpattro in Europe

|About: Alnylam Pharmaceutical... (ALNY)|By:, SA News Editor

London-based Silence Therapeutics plc (OTCPK:SLNCF) has filed a cross-border interim injunction application in the Netherlands asking the courts to stop Alnylam Pharmaceuticals (ALNY +1.2%) from commercializing ONPATTRO (patisiran) in the EU while potential infringement on its European patent EP 3 222 724B can be adjudicated. The application was filed in the Netherlands because that is where ALNY holds its marketing application.

A UK-based trial is set to begin in December.

Subscribe for full text news in your inbox